Skip to content

Dexmedetomidine versus fentanyl as adjuvants to TIVA in craniotomies

Dexmedetomidine and fentanyl as adjuvants to propofol based total intravenous anaesthesia in patients undergoing elective supratentorial craniotomies for intracranial space occupying lesions: A randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064677
Enrollment
82
Registered
2024-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Group A: Dexmedetomidine is used as an adjuvant to propofol-based TIVA: Propofol consumption will be measured till the end of the surgery Control Intervention1: Group B: Fentanyl is use

Sponsors

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between 18-70 years of age including all genders. 2. American Society of Anaesthesiologists Physical status I to III. 3. Scheduled for elective craniotomy for supratentorial brain tumors under general anaesthesia.

Exclusion criteria

Exclusion criteria: 1. Patients refusing to give consent. 2. Patient with body mass index = 35 kg/m². 3. Pregnant patients. 4. Patients allergic to any of the study drugs. 5. Preoperative GCS less than 13. 6. Patients with bleeding diathesis

Design outcomes

Primary

MeasureTime frame
To assess the mean propofol consumption at the end of the surgery (in mcg/kg/min) in all the patients.Timepoint: At the end of the surgery

Secondary

MeasureTime frame
To compare the intra-operative hemodynamic profile between the two groups.Timepoint: At 5-minute intervals till 15 minutes after induction, followed by every 30 minutes till the end of the surgery

Countries

India

Contacts

Public ContactDr Anju Grewal

All India Institute of Medical Sciences Bathinda

dranjugrewal@gmail.com9815482626

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026